Secretome and immune cell attraction analysis of head and neck cancers
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03809-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Tara Muijlwijk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Tumor Microenvironment, Cell Movement, Dendritic Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Center Amsterdam (CCA).
Abstract (Originalsprache)
Immune checkpoint inhibitors are approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) but the response rate is only 13–18%. For an effective antitumor immune response, trafficking of immune cells to the tumor microenvironment (TME) is essential. We aimed to better understand immune cell migration as well as the involved chemokines in HNSCC. A transwell assay was used to study immune cell migration toward TME-conditioned medium. While T cell migration was not observed, conventional dendritic cell (cDC) migration was induced by TME-conditioned media. cDC migration correlated with various proteins in the TME secretome. CCL8, CXCL5, CCL13 and CCL7 were tested in validation experiments and addition of these chemokines induced cDC migration. Using single cell RNA-sequencing, we observed expression of CCL8, CXCL5, CCL13 and CCL7 in cancer-associated fibroblasts (CAFs). Depleting fibroblasts led to reduced cDC migration. Thus CAFs, while often seen as suppressors of antitumor immunity, play a role in attracting cDCs toward the head and neck cancer TME, which might be crucial for effective antitumor immunity and response to therapies. Indeed, we found RNA expression signatures of the indicated chemokines, cDC and CAF subpopulations, to be significantly higher in baseline tumor specimen of patients with a major pathological response to pre-surgical anti-PD-1 treatment compared to non-responding patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands.
- Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
- Amsterdam Institute for Immunology and Infectious Diseases, Cancer Immunology, Amsterdam, Netherlands.
- Amsterdam UMC, Location Vrije Universiteit Amsterdam, Medical Oncology, Amsterdam, Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands.
- Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands. r.vandeven@amsterdamumc.nl.
Förderung
- Cancer Center Amsterdam (CCA)
Zitieren
APA
Muijlwijk, T., Wondergem, N. E., Ekhlas, F., Remkes, N., Nijenhuis, D. N. L. M., Fritz, L., Ganzevles, S. H., Miedema, I. H. C., Leemans, C. R., Poell, J. B., Brakenhoff, R. H., & van de Ven, R. (2024). Secretome and immune cell attraction analysis of head and neck cancers. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03809-z
Vancouver
Muijlwijk T, Wondergem NE, Ekhlas F, Remkes N, Nijenhuis DNLM, Fritz L, et al. Secretome and immune cell attraction analysis of head and neck cancers. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03809-z
BibTeX
@article{Muijlwijk2024,
author = {Muijlwijk, Tara and Wondergem, Niels E and Ekhlas, Fatima and Remkes, Naomi and Nijenhuis, Dennis N L M and Fritz, Lennart and Ganzevles, Sonja H and Miedema, Iris H C and Leemans, C René and Poell, Jos B and Brakenhoff, Ruud H and van de Ven, Rieneke},
title = {Secretome and immune cell attraction analysis of head and neck cancers},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03809-z}
}
EUVIMED